Overview

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Status:
RECRUITING
Trial end date:
2025-05-20
Target enrollment:
Participant gender:
Summary
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Phase:
PHASE3
Details
Lead Sponsor:
Dongkook Pharmaceutical Co., Ltd.
Treatments:
Leuprolide